Acute myeloid Leukemia (AML)

Dec 06, 2022

Nkarta’s Anti-CD19 Allogeneic CAR-NK Cell Therapy, NKX019; Eisai Presents Results of lecanemab for Alzheimer’s Disease; EQRx’s Aumolertinib for EGFR-Mutated NSCLC; FDA Approves Olutasidenib for IDH1-Mutated R/R AML; FDA Orphan Drug Designation to AUM302 for Neuroblastoma; X4 Pharma Announces Results for WHIM Syndrome Drug

May 10, 2022

AstraZeneca’s Farxiga; Incyte’s Jakavi; FDA Fast Track Status to HM43239 for R/R AML; Idorsia’s Insomnia Drug Quviviq; EU Approves Kymirah For Follicular Lymphoma; Perrigo Acquires HRA Pharma; Janssen Submits Marketing Authorisation Application to EMA

Oct 20, 2020

Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19

Mar 03, 2015

Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Newsletter/Whitepaper